# GRAPES-SHAP vs Advanced Baseline RAG — Comparative Study

## 1. Experimental Setup

- **Baseline (control):** hybrid dense (MiniLM + FAISS) + BM25 retrieval with reciprocal-rank fusion, answered directly by DeepSeek (`deepseek-chat`).
- **GRAPES-SHAP (proposed):** the full 12-step pipeline — query expansion, hybrid retrieval + MMR, causal KG + edge-biased GNN, latent world-model simulation, Tree-of-Thought planning, deep-ensemble uncertainty, hallucination self-check, and SHAP attribution — used to condition the same DeepSeek model.
- **Protocol:** both systems answer the *identical* set of 10 complex clinical vignettes over the same MedMCQA evidence corpus.

## 2. Aggregate Results

| Metric | Baseline RAG | GRAPES-SHAP |
|---|---|---|
| Clinical concept coverage | 0.700 | **0.967** |
| Answer structure completeness | 0.500 | **0.838** |
| Evidence citations (avg) | 2.00 | **5.10** |
| Stated confidence | 0.910 | 0.700 |
| SHAP evidence attribution | — (none) | **1.281** |
| Calibrated uncertainty | No | **Yes (deep ensemble)** |
| World-model planning | No | **Yes (Tree-of-Thought)** |

## 3. Per-Prompt Side-by-Side

### Prompt 1 — Acute Coronary Syndrome

**Clinical vignette:** A 58-year-old male with history of hypertension and diabetes presents to the ED with acute onset chest pain radiating to left arm and jaw. EKG shows ST elevation in leads II, III, aVF. Troponin is elevated at 2.5 ng/mL. Patient reports chest pain for 45 minutes. What is the most likely diagnosis and appropriate immediate management?

**Expected concepts:** Acute MI, STEMI, Immediate PCI/Thrombolysis

**Concept coverage:** baseline 0.67 vs GRAPES 1.00 · GRAPES mean |SHAP| = 1.082

<details><summary>Baseline RAG answer</summary>


(1) Most likely diagnosis: Inferior wall ST-elevation myocardial infarction (STEMI).  
(2) Immediate management: Emergency reperfusion therapy (either primary percutaneous coronary intervention or thrombolytic therapy, depending on local resources and time from symptom onset).  
(3) Rationale: The patient’s symptoms, EKG showing ST elevation in leads II, III, aVF, and elevated troponin are diagnostic of inferior wall MI [2]; immediate management focuses on reperfusion [3].  

Confidence: 0.95

</details>

<details><summary>GRAPES-SHAP answer</summary>


**1. Chain-of-Thought Reasoning**

*   **Diagnosis Confirmation:** The patient presents with classic symptoms of acute myocardial infarction (retrosternal chest pain radiating to the left arm and jaw) and risk factors (hypertension, diabetes, age). The EKG shows ST elevation in leads II, III, and aVF, which is diagnostic of an **inferior wall ST-elevation myocardial infarction (STEMI)** [2]. The elevated troponin (2.5 ng/mL) confirms myocardial injury. The duration of pain (45 minutes) is within the window for emergent reperfusion therapy.
*   **Immediate Management Priority:** The cornerstone of STEMI management is rapid reperfusion to restore blood flow to the infarct-related artery (likely the right coronary artery or left circumflex artery). The evidence supports that the next appropriate step after diagnosis is immediate intervention [1]. Given the patient is within 12 hours of symptom onset and has no contraindications, the primary decision is between **percutaneous coronary intervention (PCI)** and **thrombolytic therapy**.
*   **Treatment Selection:** The simulation results indicate the best treatment plan includes [1, 43, 42, 23]. While the specific codes are not directly interpretable, the context of the evidence and standard guidelines points to PCI as the preferred strategy when available. Evidence [3] mentions that thrombolytic therapy is *not* given in a specific scenario (likely due to late presentation or contraindications), but for this patient presenting early (45 minutes), both are options. However, PCI is superior in terms of efficacy and lower risk of intracranial hemorrhage. The "best treatment plan" score (-0.29) suggests a moderate benefit, likely reflecting the need for PCI over thrombolysis.
*   **Supportive Care:** In addition to reperfusion, the patient requires antiplatelet therapy (aspirin, P2Y12 inhibitor), anticoagulation (heparin), and pain management (morphine). Beta-blockers and ACE inhibitors are indicated for long-term management but should be initiated cautiously in the acute setting, especially with inferior MI (risk of bradycardia/hypotension).

**2. Treatment Recommendation**

*   **Immediate Reperfusion:** **Primary Percutaneous Coronary Intervention (PCI)** is the recommended strategy. This should be performed within 90 minutes of first medical contact. If PCI is not available within 120 minutes, **thrombolytic therapy** (e.g., tenecteplase or alteplase) should be administered.
*   **Pharmacologic Therapy (to be given immediately):**
    *   **Aspirin:** 325 mg chewed immediately.
    *   **P2Y12 Inhibitor:** Ticagrelor 180 mg loading dose (or clopidogrel 600 mg if ticagrelor is unavailable).
    *   **Anticoagulation:** Unfractionated heparin (60 U/kg bolus, max 4000 U, then 12 U/kg/hr infusion, max 1000 U/hr) or enoxaparin (1 mg/kg SC every 12 hours).
    *   **Pain Control:** Morphine sulfate 2-4 mg IV, titrated to pain relief.
    *   **Oxygen:** Only if O2 saturation is <90%.
*   **Contraindications to Check:** Before thrombolysis, rule out: history of intracranial hemorrhage, recent major surgery, active bleeding, severe uncontrolled hypertension (>180/110 mmHg), or recent stroke.

**3. Risk-Benefit Summary**

*   **Major Benefits:**
    *   **Reduced Mortality:** Prompt reperfusion (PCI or thrombolysis) reduces 1-year mortality by approximately 30-50% compared to no reperfusion.
    *   **Preserved Left Ventricular Function:** Restoring blood flow limits infarct size, preserving cardiac function and reducing the risk of heart failure.
    *   **Symptom Relief:** Rapid resolution of chest pain and associated symptoms.
*   **Major Risks:**
    *   **Bleeding:** Both PCI (access site bleeding, retroperitoneal bleed) and thrombolysis (intracranial hemorrhage ~0.5-1%, major bleeding ~5-10%) carry significant bleeding risks. This patient's age (58) and diabetes increase bleeding risk slightly.
    *   **Reperfusion Arrhythmias:** Ventricular tachycardia or fibrillation, or bradyarrhythmias (especially with inferior MI), can occur during reperfusion.
    *   **Contrast Nephropathy:** Risk is elevated in patients with diabetes and hypertension, though usually transient.
    *   **Hypotension:** Inferior MI can cause right ventricular involvement, leading to hypotension, especially with nitrates or morphine.

**4. Follow-up Protocol**

*   **Monitoring (First 24 hours):**
    *   Continuous cardiac monitoring in a CCU/ICU setting.
    *   Vital signs every 1-2 hours.
    *   Serial EKGs (every 30 minutes for first 2 hours, then every 6 hours) to assess for reperfusion (resolution of ST elevation >50%).
    *   Troponin levels at 6 and 12 hours post-presentation.
    *   Monitor for bleeding (access site, GI, intracranial).
*   **Contingency Plans:**
    *   **If PCI fails or is delayed:** Administer thrombolytic therapy if within 12 hours of symptom onset and no contraindications.
    *   **If bleeding occurs:** Hold anticoagulation/antiplatelet therapy, assess source, and consider transfusion if hemodynamically significant.
    *   **If arrhythmias develop:** Treat per ACLS protocols (e.g., amiodarone for VT, atropine for bradycardia).
    *   **If hypotension develops:** Assess for right ventricular infarction (elevated JVP, clear lungs). Give IV fluids (normal saline bolus) and avoid nitrates.
*   **Long-term Management (Post-discharge):**
    *   Dual antiplatelet therapy (aspirin + ticagrelor) for 12 months.
    *   Beta-blocker (e.g., metoprolol 25-50 mg BID) titrated to heart rate.
    *   ACE inhibitor (e.g., ramipril 2.5-5 mg daily) for LV dysfunction or hypertension.
    *   High-intensity statin (e.g., atorvastatin 80 mg daily).
    *   Lifestyle modification: smoking cessation, diet, exercise, glycemic control.

**5. Confidence Assessment**

**Confidence: 0.85**

*   **Rationale:** The diagnosis of inferior STEMI is unequivocal based on EKG and troponin [2]. The recommendation for primary PCI is strongly supported by evidence and guidelines as the gold standard for STEMI management. The confidence is not 1.0 because:
    *   The simulation results are based on a model with some uncertainty (score -0.29).
    *   Patient-specific factors (e.g., exact bleeding risk, renal function, availability of PCI) are not fully detailed in the query.
    *   The evidence provided [1]-[6] is from question banks, not direct clinical trial data, but the principles are well-established.

**6. Key Evidence**

*   **[2]** Confirms the diagnosis of inferior wall MI based on ST elevation in leads II, III, and aVF.
*   **[1]** Supports the next appropriate step after diagnosis is an ECG (already done) and implies the need for immediate management.
*   **[3]** Highlights that thrombolytic therapy is not always given (e.g., if contraindicated or if PCI is preferred), reinforcing the need for careful selection.
*   **[6]** Suggests that management includes multiple components (all of the above), supporting a multi-faceted approach (antiplatelet, anticoagulation, etc.).

</details>


---

### Prompt 2 — Sepsis & Infection

**Clinical vignette:** A 72-year-old female with COPD presents with fever (39.2C), altered mental status, and tachycardia (HR 118). Labs show WBC 15.2K, lactate 3.2 mmol/L, and creatinine increased from baseline. Imaging shows pneumonia. Blood cultures pending. Patient is hypotensive (BP 88/52). What is the first-line treatment approach?

**Expected concepts:** Sepsis, Septic shock, Broad-spectrum antibiotics

**Concept coverage:** baseline 0.33 vs GRAPES 1.00 · GRAPES mean |SHAP| = 0.977

<details><summary>Baseline RAG answer</summary>


(1) Most likely diagnosis: Septic shock secondary to pneumonia.  
(2) Immediate management: Aggressive fluid resuscitation, oxygen supplementation, and norepinephrine for hypotension if fluids fail [3].  
(3) Rationale: Evidence [3] directly states that for septic shock with hypotension (BP 70/50), norepinephrine is used to stabilize blood pressure after fluid resuscitation.  

Confidence: 0.9

</details>

<details><summary>GRAPES-SHAP answer</summary>


**1. Chain-of-Thought Reasoning**

*   **Step 1: Diagnosis Confirmation:** The patient presents with fever, altered mental status, tachycardia, hypotension (BP 88/52), elevated lactate (3.2 mmol/L), and evidence of infection (pneumonia on imaging, elevated WBC). This constellation meets the criteria for **septic shock**.
*   **Step 2: Immediate Priorities:** The core principles of septic shock management are: (1) source control, (2) early antibiotics, and (3) hemodynamic support. The evidence supports this approach.
*   **Step 3: Hemodynamic Support:** The patient is hypotensive despite the presence of infection. Evidence [3] directly addresses this scenario: "Treatment of septic shock include aggressive fluid resuscitation and oxygen supplementation. If hypotension persists, dopamine is the drug of choice to raise arterial pressure and to maintain BP. When [dopamine fails], norepinephrine is used." Given the patient's age (72) and COPD, norepinephrine is often preferred over dopamine due to a more favorable side effect profile (less tachyarrhythmia risk), but the evidence explicitly states dopamine first. However, the simulation results (Best treatment plan: [4, 31, 45, 29]) and the clinical context of severe hypotension (BP 88/52) suggest that norepinephrine is the appropriate first-line vasopressor for septic shock, as it is more potent and has a more predictable effect. The evidence [3] provides a historical perspective but modern guidelines favor norepinephrine.
*   **Step 4: Antibiotics:** Broad-spectrum antibiotics must be started immediately after blood cultures are drawn. The patient has community-acquired pneumonia (CAP) with sepsis. Empiric therapy should cover typical and atypical pathogens. A common regimen is a beta-lactam (e.g., ceftriaxone) plus a macrolide (e.g., azithromycin) or a respiratory fluoroquinolone (e.g., levofloxacin). The evidence [6] highlights the importance of broad-spectrum antibiotics in septic patients.
*   **Step 5: Source Control:** The source is pneumonia. No immediate procedural intervention is needed unless there is an empyema or complicated effusion. The evidence [1] describes a procedure (likely a thoracentesis or drainage) being performed when a patient does not improve, which is a contingency plan.
*   **Step 6: Other Considerations:** The patient has COPD. This increases the risk of respiratory failure. Oxygen supplementation is critical. The patient's altered mental status and elevated creatinine suggest end-organ dysfunction (CNS and renal), which is consistent with septic shock. The evidence [4] describes a different condition (TTP) and is not relevant here.

**2. Treatment Recommendation**

*   **Immediate Actions:**
    *   **Oxygen:** Administer high-flow oxygen to maintain SpO2 > 92%. Consider non-invasive ventilation (BiPAP) if respiratory distress develops.
    *   **IV Fluids:** Administer a 30 mL/kg crystalloid bolus (e.g., 2L of Lactated Ringer's or Normal Saline) over the first hour, monitoring for fluid overload (given COPD).
    *   **Vasopressors:** Start **Norepinephrine** as the first-line vasopressor. Begin at 5-10 mcg/min and titrate to a mean arterial pressure (MAP) of ≥ 65 mmHg.
    *   **Antibiotics:** Start empiric broad-spectrum antibiotics immediately after blood cultures.
        *   **Regimen:** **Ceftriaxone 2g IV daily** + **Azithromycin 500mg IV daily**.
        *   *Alternative:* **Levofloxacin 750mg IV daily** (if penicillin allergy or other contraindications).
    *   **Cultures:** Blood cultures (2 sets), sputum culture, and urine antigen tests (for *Legionella* and *Streptococcus pneumoniae*).

**3. Risk-Benefit Summary**

*   **Major Benefits:**
    *   **Hemodynamic stabilization:** Norepinephrine rapidly increases blood pressure, improving perfusion to vital organs (brain, kidneys, heart) and reducing the risk of multi-organ failure.
    *   **Infection control:** Early, appropriate antibiotics reduce mortality in septic shock.
    *   **Improved oxygenation:** Oxygen therapy prevents hypoxemia and respiratory failure.

*   **Major Risks:**
    *   **Vasopressor-related:** Norepinephrine can cause tachyarrhythmias (especially in an elderly patient with tachycardia), peripheral ischemia (rare), and increased myocardial oxygen demand.
    *   **Fluid overload:** The patient has COPD, which may predispose to pulmonary edema if fluids are given too aggressively. Careful monitoring of lung sounds and oxygen saturation is needed.
    *   **Antibiotic-related:** Ceftriaxone can cause *C. difficile* colitis, allergic reactions, and renal impairment (though less than aminoglycosides). Azithromycin can cause QT prolongation (risk of arrhythmia).
    *   **Progression to respiratory failure:** Despite treatment, the patient may require intubation and mechanical ventilation.

**4. Follow-Up Protocol**

*   **Monitoring (First 6 hours):**
    *   **Vital signs:** Continuous monitoring of BP, HR, RR, SpO2, and temperature every 15 minutes until stable.
    *   **Lactate:** Recheck lactate at 2-4 hours. Goal is a decrease of >20% or normalization.
    *   **Urine output:** Place a Foley catheter. Goal is >0.5 mL/kg/hour.
    *   **Mental status:** Reassess hourly.
    *   **Respiratory status:** Monitor for signs of respiratory failure (increased work of breathing, desaturation, hypercapnia).
*   **Contingency Plans:**
    *   **If hypotension persists despite norepinephrine (e.g., MAP < 65 mmHg):** Add **Vasopressin** (0.03 units/min) as a second-line agent.
    *   **If respiratory failure develops:** Prepare for intubation and mechanical ventilation. Use lung-protective ventilation settings (low tidal volume, 6 mL/kg ideal body weight).
    *   **If no clinical improvement in 48-72 hours:** Reassess for complications (e.g., empyema, resistant organisms, other sources of infection). Consider a CT chest or bronchoscopy.
    *   **If blood cultures grow a specific organism:** Narrow antibiotics based on sensitivities.

**5. Confidence Assessment**

**Confidence: 0.85**

*   **Rationale:** The diagnosis of septic shock is clear. The treatment plan (fluids, vasopressors, antibiotics) is well-established by evidence [3] and clinical guidelines. The choice of norepinephrine over dopamine is supported by modern practice and the patient's age/COPD status. The antibiotic choice is standard for CAP. The main uncertainty is the patient's response to fluids (given COPD) and the specific pathogen, which will be clarified by cultures. The evidence [1] and [6] support the general approach but are not specific to this case. The evidence [2] and [5] are not relevant. The evidence [4] is for a different disease (TTP).

**6. Key Evidence**

*   **[3]:** Directly supports the use of vasopressors (norepinephrine/dopamine) for septic shock with hypotension.
*   **[1]:** Supports the general approach of aggressive fluid resuscitation and antibiotics in sepsis.
*   **[6]:** Supports the use of broad-spectrum antibiotics in a septic patient with an infectious source.

</details>


---

### Prompt 3 — Metabolic Crisis

**Clinical vignette:** A 34-year-old Type 1 diabetic presents with polyuria, polydipsia, and dyspnea. pH is 7.15, HCO3 12, glucose 524 mg/dL, serum osmolarity 310 mOsm/kg, anion gap 18. Urinalysis shows large ketones. Patient consumed alcohol yesterday. What metabolic emergency is present?

**Expected concepts:** DKA, Metabolic acidosis, Insulin therapy

**Concept coverage:** baseline 1.00 vs GRAPES 1.00 · GRAPES mean |SHAP| = 1.143

<details><summary>Baseline RAG answer</summary>


(1) **Most likely diagnosis:** Diabetic ketoacidosis (DKA)  
(2) **Immediate management:** Administration of short-acting insulin  
(3) **Rationale:** The patient meets DKA criteria (glucose >250 mg/dL, pH <7.3, HCO3 <18, elevated ketones) with polyuria, polydipsia, dyspnea, and a history of alcohol consumption, which can precipitate DKA [1][3].  

Confidence: 0.95

</details>

<details><summary>GRAPES-SHAP answer</summary>


**Chain-of-thought reasoning**

1.  **Identifying the Primary Diagnosis:** The patient is a 34-year-old with Type 1 diabetes. The presenting symptoms (polyuria, polydipsia, dyspnea) and lab values (pH 7.15, HCO3 12, glucose 524 mg/dL, anion gap 18, large ketones in urine) are classic for diabetic ketoacidosis (DKA). The low pH (<7.3), low bicarbonate (<18 mEq/L), hyperglycemia (>250 mg/dL), and ketonuria fulfill the diagnostic criteria for DKA as described in [3]. The history of alcohol consumption is a potential precipitating factor but does not change the primary diagnosis of DKA.

2.  **Differentiating from Other Conditions:**
    *   **Hyperosmolar Hyperglycemic State (HHS):** While the serum osmolarity is elevated (310 mOsm/kg), it is not typically the primary driver in DKA. The hallmark of DKA is significant ketosis and metabolic acidosis, which are present here. HHS usually has a higher osmolarity (>320 mOsm/kg) and minimal ketones.
    *   **Alcoholic Ketoacidosis (AKA):** This can present with similar labs (high anion gap metabolic acidosis, ketones) but typically occurs in patients with chronic alcohol use, often with lower or normal blood glucose levels. The patient's severe hyperglycemia (524 mg/dL) and history of Type 1 diabetes make DKA the far more likely diagnosis.
    *   **Uremic Acidosis:** This is ruled out by the absence of a history of chronic kidney disease and the presence of large ketones [6].
    *   **Hypercalcemia:** This is ruled out by the normal ECG (no narrowed QT interval) and the specific lab findings of DKA [4].

3.  **Formulating the Treatment Plan:** The cornerstone of DKA management is the administration of short-acting insulin to reverse ketonemia and acidosis [1][3]. The simulation results suggest a treatment plan with a score of -0.17, which is not ideal. The predicted outcomes (negative survival, high readmission risk) are likely artifacts of the simulation model and do not reflect the standard of care. The immediate, evidence-based treatment is intravenous (IV) regular insulin.

**Treatment recommendation**

*   **Immediate Therapy:** Administer **intravenous regular insulin**.
    *   **Initial Bolus:** 0.1 units/kg IV bolus.
    *   **Continuous Infusion:** 0.1 units/kg/hour IV infusion.
*   **Supportive Care:**
    *   **Fluid Resuscitation:** Start with 1-2 liters of 0.9% normal saline over the first 1-2 hours, then switch to 0.45% normal saline once glucose falls below 250 mg/dL.
    *   **Electrolyte Repletion:** Monitor potassium closely. If K+ is <5.5 mEq/L, add 20-40 mEq/L of potassium to each liter of IV fluid. Replete phosphate if levels are <1.0 mg/dL.
    *   **Bicarbonate:** Not indicated for pH >6.9. This patient's pH is 7.15, so no bicarbonate is needed [1].
*   **Monitoring:** Check blood glucose hourly. Check serum electrolytes (including bicarbonate, anion gap) and venous pH every 2-4 hours.

**Risk-benefit summary**

*   **Major Benefits:**
    *   Rapid reversal of metabolic acidosis and ketonemia [1].
    *   Prevention of progression to coma and death.
    *   Restoration of normal glucose utilization.
*   **Major Risks:**
    *   **Hypoglycemia:** Can occur if insulin is continued without adequate glucose monitoring and dextrose administration once glucose falls below 250 mg/dL.
    *   **Hypokalemia:** Insulin drives potassium into cells, which can cause dangerous cardiac arrhythmias if not monitored and repleted.
    *   **Cerebral Edema:** Rare but serious risk, especially in children and young adults, if fluids are given too aggressively or glucose is lowered too rapidly.

**Follow-up protocol**

*   **Hourly:** Check blood glucose (goal: decrease by 50-75 mg/dL per hour).
*   **Every 2-4 hours:** Check serum electrolytes (Na+, K+, Cl-, HCO3-), BUN, creatinine, and venous pH. Monitor anion gap (goal: closure of anion gap).
*   **Continuous:** Cardiac monitoring for arrhythmias due to potassium shifts.
*   **Transition:** When the anion gap is closed (normalized) and the patient can eat, transition from IV insulin to subcutaneous insulin (e.g., glargine for basal, lispro for prandial). Overlap IV and subcutaneous insulin by 1-2 hours to prevent rebound hyperglycemia.
*   **Contingency:** If glucose falls below 250 mg/dL before the anion gap closes, add 5% dextrose to IV fluids and continue insulin infusion. If potassium falls below 3.3 mEq/L, hold insulin and replete potassium first.

**Confidence assessment**

**0.95** (High confidence). The diagnosis is unequivocal based on the classic presentation and lab values [1][2][3]. The treatment with insulin is the standard of care. The only minor uncertainty is the exact precipitating factor (alcohol vs. other illness), but this does not change the immediate management.

**Key evidence**

[1], [2], [3]

</details>


---

### Prompt 4 — Neurological Emergency

**Clinical vignette:** A 65-year-old right-handed male with atrial fibrillation (not anticoagulated) presents with acute onset aphasia and right-sided weakness (arm MRC 2/5, leg 3/5). Last known normal was 1.5 hours ago. NIHSS 14. CT head shows no hemorrhage. What is the time-sensitive intervention?

**Expected concepts:** Acute stroke, tPA, Thrombolytic therapy

**Concept coverage:** baseline 0.33 vs GRAPES 1.00 · GRAPES mean |SHAP| = 1.358

<details><summary>Baseline RAG answer</summary>


(1) Most likely diagnosis: Acute ischemic stroke due to left middle cerebral artery (MCA) territory occlusion (superior division) [3].  
(2) Immediate management: Administer intravenous thrombolysis (alteplase) within 4.5 hours of symptom onset, given no hemorrhage on CT and last known normal 1.5 hours ago [2].  
(3) Rationale: The patient's aphasia and right-sided weakness localize to the left MCA territory [3], and acute ischemic stroke in atrial fibrillation requires urgent thrombolysis if no contraindications [2].  

Confidence: 0.95

</details>

<details><summary>GRAPES-SHAP answer</summary>


**Chain-of-thought reasoning**

1.  **Patient Presentation:** A 65-year-old male with atrial fibrillation (AF) and no anticoagulation presents with acute onset aphasia and right-sided weakness (NIHSS 14). The aphasia and right-sided weakness localize to the left hemisphere. The last known normal was 1.5 hours ago, placing the patient well within the 4.5-hour window for intravenous thrombolysis.
2.  **Stroke Etiology:** The patient has atrial fibrillation, a major risk factor for cardioembolic stroke. The evidence [2] confirms that a patient with mitral stenosis and AF presenting with acute focal weakness is most likely having an ischemic stroke. The aphasia in this right-handed patient is due to a left hemisphere lesion, consistent with the typical language dominance [1].
3.  **Imaging:** The CT head shows no hemorrhage, which is the primary contraindication for thrombolysis. The evidence [5] highlights that a CT scan is a critical initial investigation in a patient on warfarin with AF who is unconscious, and by extension, in any acute stroke patient to rule out hemorrhage. This patient is not on anticoagulation, further reducing the risk of hemorrhagic conversion from thrombolysis.
4.  **Time-Sensitive Intervention:** Given the clear ischemic stroke with a known onset time of 1.5 hours, no hemorrhage on CT, and no contraindications (no anticoagulation, no recent surgery, no active bleeding), the standard of care is intravenous thrombolysis with alteplase (tPA) or tenecteplase (TNK). The evidence [6] describes a patient with new AF and a transient ischemic attack, but this patient has a persistent deficit, making thrombolysis the appropriate acute intervention.
5.  **Simulation Results:** The simulation suggests a best treatment plan with a negative plan score, which is difficult to interpret directly. However, the predicted outcomes (1-year survival, readmission, complication rate) are all near zero with wide confidence intervals, indicating high uncertainty in the model's predictions. This does not change the clinical imperative for thrombolysis based on established guidelines and the patient's presentation.
6.  **Conclusion:** The most time-sensitive intervention is **intravenous thrombolysis**. The patient is an excellent candidate.

**Treatment recommendation**

- **Drug:** Alteplase (tPA) or Tenecteplase (TNK).
- **Dose (Alteplase):** 0.9 mg/kg (maximum 90 mg total). Give 10% of the total dose as an initial intravenous bolus over 1 minute, followed by the remaining 90% as an intravenous infusion over 60 minutes.
- **Dose (Tenecteplase):** 0.25 mg/kg (maximum 25 mg) as a single intravenous bolus over 5 seconds.
- **Schedule:** Administer immediately after confirming eligibility and obtaining consent. The patient is within the 4.5-hour window.

**Risk-benefit summary**

- **Major Benefits:**
    - **Improved functional outcome:** Thrombolysis significantly increases the odds of a favorable neurological outcome (modified Rankin Scale 0-1) at 3 months. For a patient with an NIHSS of 14, the number needed to treat (NNT) for one additional excellent outcome is approximately 8-10.
    - **Reduced disability:** Early reperfusion can salvage the ischemic penumbra, potentially reducing the severity of permanent aphasia and hemiparesis.
- **Major Risks:**
    - **Symptomatic Intracranial Hemorrhage (sICH):** The primary risk, occurring in approximately 2-7% of patients. Risk is increased by age, high NIHSS, and hyperglycemia, but this patient has no major additional risk factors (no anticoagulation, no hemorrhage on CT).
    - **Systemic Bleeding:** Risk of major extracranial bleeding (e.g., gastrointestinal, retroperitoneal) is low (<2%).
    - **Angioedema:** Orolingual angioedema can occur, especially in patients on ACE inhibitors.

**Follow-up protocol**

- **Immediate (First 24 hours):**
    - **Monitoring:** Admit to a stroke unit or intensive care unit. Monitor blood pressure (target <180/105 mmHg), neurological status (NIHSS every 15 minutes for 2 hours, then every 30 minutes for 6 hours, then hourly for 24 hours), and for signs of bleeding.
    - **Imaging:** Obtain a non-contrast CT head at 24 hours post-thrombolysis (or sooner if neurological deterioration occurs) to rule out hemorrhage before starting antithrombotic therapy.
    - **Anticoagulation:** Do not administer anticoagulants (e.g., heparin, warfarin, DOACs) for 24 hours post-thrombolysis. After the 24-hour CT confirms no hemorrhage, start anticoagulation for atrial fibrillation (e.g., apixaban, rivaroxaban, edoxaban) to prevent recurrent stroke.
- **Contingency Plan:**
    - **If neurological deterioration occurs (e.g., worsening aphasia, headache, vomiting):** Stop the infusion (if still running), obtain an emergency CT head to rule out hemorrhage. If sICH is confirmed, reverse thrombolysis (cryoprecipitate for fibrinogen, platelets if thrombocytopenic) and consult neurosurgery.
    - **If angioedema develops:** Stop the infusion, administer IV diphenhydramine, famotidine, and methylprednisolone. If airway compromise, consider epinephrine and intubation.

**Confidence assessment**

**Confidence: 0.95**

This recommendation is based on a large body of high-quality evidence from randomized controlled trials (e.g., NINDS, ECASS III) and is the standard of care for acute ischemic stroke within 4.5 hours. The patient's presentation is classic, and there are no major contraindications. The simulation results do not alter this well-established clinical pathway. The small uncertainty (0.05) accounts for the rare possibility of an undetected contraindication (e.g., subtle imaging finding, unreported recent surgery).

**Key evidence**

- **[2]** Confirms the diagnosis of ischemic stroke in a patient with AF and acute focal weakness.
- **[5]** Reinforces the necessity of a CT scan to rule out hemorrhage before intervention.
- **[1]** Provides context for the aphasia localization, confirming a left hemisphere stroke.
- **[6]** Illustrates a similar clinical scenario (AF + stroke) but highlights the need for acute intervention in a patient with persistent deficits.

</details>


---

### Prompt 5 — Respiratory Failure

**Clinical vignette:** A 45-year-old smoker with COPD (FEV1 35%) presents with increased dyspnea, yellow sputum, and leg edema. ABG shows pH 7.28, pCO2 68, pO2 48 on RA. JVP elevated, crackles present, S3 gallop. CXR shows infiltrates. BNP 450. What constellation of problems is present?

**Expected concepts:** COPD exacerbation, Cor pulmonale, Heart failure

**Concept coverage:** baseline 1.00 vs GRAPES 1.00 · GRAPES mean |SHAP| = 1.774

<details><summary>Baseline RAG answer</summary>


(1) Most likely diagnosis: Acute exacerbation of COPD with type II respiratory failure (hypercapnic respiratory failure) and superimposed cardiogenic pulmonary edema (right heart failure).  
(2) Immediate management: Noninvasive positive pressure ventilation (BiPAP) for respiratory failure, diuretics for volume overload (leg edema, elevated JVP, BNP 450), and bronchodilators/corticosteroids for COPD exacerbation.  
(3) Rationale: ABG shows pH 7.28, pCO2 68, pO2 48 indicating type II respiratory failure typical of COPD exacerbation [2]; elevated JVP, leg edema, S3 gallop, BNP 450, and CXR infiltrates suggest cardiogenic pulmonary edema [3].  

Confidence: 0.9

</details>

<details><summary>GRAPES-SHAP answer</summary>


**Chain-of-thought reasoning**

1.  **Problem Identification:** The patient is a 45-year-old smoker with severe COPD (FEV1 35%). He presents with acute dyspnea, purulent sputum, and signs of right heart failure (elevated JVP, leg edema, S3 gallop). The ABG shows respiratory acidosis (pH 7.28, pCO2 68) with hypoxemia (pO2 48 on room air), which is **Type II respiratory failure** consistent with an acute exacerbation of COPD [2]. The elevated BNP (450) and physical exam findings (JVP, S3, crackles) indicate concomitant **acute heart failure** (likely right-sided or biventricular). The CXR shows infiltrates, which could represent pneumonia or pulmonary edema. The constellation is therefore **acute-on-chronic respiratory failure (Type II) due to COPD exacerbation, complicated by acute heart failure and possible pneumonia**.

2.  **Pathophysiology:** The patient's severe COPD (chronic bronchitis with mucus hypersecretion [4]) is the underlying lung disease. The acute exacerbation (likely infectious) has worsened ventilation-perfusion mismatch, leading to hypercapnia and hypoxemia [2]. The resulting hypoxemia and pulmonary hypertension (suggested by loud P2 in evidence [1]) have precipitated right heart strain/failure (cor pulmonale), evidenced by the elevated JVP, leg edema, and elevated BNP. The crackles and S3 gallop suggest left heart involvement as well, possibly due to biventricular failure or fluid overload.

3.  **Treatment Priority:** The immediate priorities are:
    *   **Address respiratory failure:** Non-invasive ventilation (NIV) is first-line for acute hypercapnic respiratory failure in COPD exacerbation.
    *   **Treat the exacerbation:** Bronchodilators, corticosteroids, and antibiotics (for purulent sputum).
    *   **Manage heart failure:** Diuresis to reduce preload and edema, while avoiding over-diuresis that could worsen ventilation-perfusion matching.
    *   **Identify and treat infection:** Sputum cultures and empiric antibiotics.

**Treatment recommendation**

*   **Immediate (within 1 hour):**
    *   **Non-invasive ventilation (NIV):** Initiate BiPAP with IPAP 10-15 cmH2O, EPAP 4-6 cmH2O, titrated to target SpO2 88-92% and reduce pCO2.
    *   **Bronchodilator:** Albuterol (salbutamol) 2.5 mg + Ipratropium 0.5 mg via nebulization every 4-6 hours.
    *   **Corticosteroid:** Methylprednisolone 40 mg IV every 6 hours for 5-7 days, then taper.
    *   **Antibiotic:** Piperacillin-tazobactam 4.5 g IV every 6 hours (covers common COPD pathogens and hospital-acquired pneumonia given severity).
    *   **Diuretic:** Furosemide 40 mg IV bolus, then reassess urine output and clinical response. Consider continuous infusion if poor response.
    *   **Supplemental oxygen:** Titrate to SpO2 88-92% (avoid hyperoxia to prevent worsening hypercapnia).

*   **Supportive:**
    *   Sputum and blood cultures.
    *   ECG and troponin to rule out acute coronary syndrome.
    *   Strict input/output monitoring.
    *   Consider pulmonary artery catheter or point-of-care ultrasound if hemodynamics are unclear.

**Risk-benefit summary**

*   **Major Benefits:**
    *   NIV reduces intubation rates and mortality in acute hypercapnic respiratory failure.
    *   Early antibiotics and steroids reduce treatment failure and length of stay.
    *   Diuresis improves heart failure symptoms and oxygenation.

*   **Major Risks:**
    *   **NIV failure:** Patient may require intubation if unable to clear secretions or if acidosis worsens.
    *   **Over-diuresis:** Can cause hypotension, acute kidney injury, and worsen ventilation-perfusion mismatch.
    *   **Steroid-induced hyperglycemia and immunosuppression.**
    *   **Antibiotic-associated diarrhea or C. difficile infection.**
    *   **Ventilator-associated pneumonia** if intubation becomes necessary.

**Follow-up protocol**

*   **Monitoring (first 24 hours):**
    *   **ABG:** Repeat at 1-2 hours after NIV initiation to assess response.
    *   **Vitals:** Continuous pulse oximetry, hourly urine output, blood pressure.
    *   **Labs:** Daily BMP, BNP, CBC, and sputum culture results.
    *   **Imaging:** Repeat CXR in 24-48 hours to assess infiltrates and pulmonary edema.

*   **Contingency Plans:**
    *   **If NIV fails (pH <7.25, pCO2 rising, altered mental status):** Proceed to endotracheal intubation and mechanical ventilation.
    *   **If diuresis inadequate:** Increase furosemide dose or add metolazone.
    *   **If hypotension develops:** Hold diuretics, consider IV fluids (cautiously) or vasopressors (e.g., norepinephrine).
    *   **If no improvement in 72 hours:** Re-evaluate for alternative diagnoses (e.g., pulmonary embolism, severe pneumonia, acute coronary syndrome).

**Confidence assessment**

**0.85** (High confidence). The evidence strongly supports the diagnosis of acute exacerbation of COPD with Type II respiratory failure [2] and the presence of heart failure (elevated BNP, JVP, S3). The treatment plan is standard of care for this common presentation. The slight uncertainty (0.15) is due to the lack of specific evidence linking the exact BNP threshold to treatment response in this scenario, and the possibility of an alternative diagnosis (e.g., pulmonary embolism) that is not fully excluded.

**Key evidence**

*   [2] – Confirms Type II respiratory failure (pH 7.2, pCO2 80) as acute exacerbation of COPD.
*   [4] – Describes chronic bronchitis (mucus hypersecretion) as a type of COPD.
*   [1] – Provides context for physical exam findings (loud P2, crackles) in a similar patient with dyspnea and smoking history, suggesting pulmonary hypertension and heart failure.
*   [3] – Differentiates cardiogenic vs. non-cardiogenic pulmonary edema on CXR, relevant to interpreting the infiltrates.

</details>


---

### Prompt 6 — Renal Crisis

**Clinical vignette:** A 52-year-old with poorly controlled hypertension and diabetes presents with severe headache, visual changes, and BP 210/130. Urinalysis shows 3+ protein and RBC casts. Creatinine 3.2 (baseline 1.0). Platelet count 85K. Schistocytes on blood smear. What hypertensive emergency syndrome is this?

**Expected concepts:** Hypertensive emergency, TMA, MAHA

**Concept coverage:** baseline 0.33 vs GRAPES 1.00 · GRAPES mean |SHAP| = 0.933

<details><summary>Baseline RAG answer</summary>


(1) Most likely diagnosis: Hypertensive emergency with thrombotic microangiopathy (suggestive of malignant hypertension or hypertensive emergency with microangiopathic hemolytic anemia).  
(2) Immediate management: Aggressive blood pressure reduction (e.g., intravenous labetalol or nicardipine) and evaluation for end-organ damage; consider plasma exchange if thrombotic thrombocytopenic purpura is suspected.  
(3) Rationale: The presentation of severe hypertension (BP 210/130), proteinuria, RBC casts, acute kidney injury (creatinine 3.2), thrombocytopenia (platelets 85K), and schistocytes indicates a hypertensive emergency with microangiopathic hemolytic anemia, as seen in malignant hypertension [1][5].  

Confidence: 0.85

</details>

<details><summary>GRAPES-SHAP answer</summary>


**Chain-of-thought reasoning:**

1.  **Symptom Analysis:** The patient presents with a severe headache, visual changes, and a blood pressure of 210/130 mmHg. This is a classic presentation of a hypertensive emergency, specifically involving end-organ damage to the central nervous system (hypertensive encephalopathy) and the kidneys.

2.  **Laboratory Findings:**
    *   **Renal:** Creatinine 3.2 mg/dL (baseline 1.0) indicates acute kidney injury. Urinalysis shows 3+ protein and RBC casts, pointing to active glomerular injury.
    *   **Hematologic:** Platelet count 85,000/μL (thrombocytopenia) and schistocytes on blood smear are the hallmark findings of microangiopathic hemolytic anemia (MAHA).

3.  **Syndrome Identification:** The combination of hypertensive emergency (severe hypertension + end-organ damage), acute kidney injury with proteinuria and hematuria, thrombocytopenia, and schistocytes is the classic pentad for **Thrombotic Microangiopathy (TMA)**. The most common cause of TMA in this clinical context (adult with hypertension and renal failure) is **Thrombotic Thrombocytopenic Purpura (TTP)** or **Hemolytic Uremic Syndrome (HUS)**. However, the evidence provided does not directly discuss TTP/HUS.

4.  **Evidence Review:**
    *   **Evidence [5]** describes a 30-year-old primigravida with severe pre-eclampsia (BP 160/110, 3+ proteinuria, platelets 80,000). This patient is not pregnant, but the hematologic and renal findings are similar. The management in [5] is MgSO4 and labetalol, which is specific to pre-eclampsia/eclampsia.
    *   **Evidence [1]** and **[2]** discuss hypertension in pregnancy, which is not applicable here.
    *   **Evidence [3]** discusses lupus nephritis (Class V), which presents with nephrotic-range proteinuria but not typically with schistocytes or severe thrombocytopenia.
    *   **Evidence [4]** describes a child with nephrotic syndrome (puffy eyes, generalized edema, no hypertension), which is not consistent with this presentation.
    *   **Evidence [6]** discusses Alport syndrome (hereditary nephritis), which causes hematuria and renal failure but not acute thrombocytopenia or schistocytes.

5.  **Conclusion:** The evidence provided does not contain a direct discussion of TTP/HUS. However, the clinical picture is pathognomonic for a thrombotic microangiopathy (TMA) syndrome. Given the absence of a clear alternative diagnosis (like pregnancy or SLE) in the query, the most likely diagnosis is **Thrombotic Thrombocytopenic Purpura (TTP)** or **atypical Hemolytic Uremic Syndrome (aHUS)**. The treatment for TTP is plasma exchange (PLEX) and corticosteroids, while aHUS is treated with eculizumab. The evidence provided is insufficient to differentiate between these two, but the presence of severe hypertension and renal failure makes aHUS a strong possibility.

**Treatment recommendation:**

*   **Immediate:** Admit to intensive care unit (ICU).
*   **Antihypertensive:** Start intravenous labetalol (20 mg IV bolus, then 1-2 mg/min infusion) or nicardipine (5 mg/hr IV infusion, titrated) to lower BP by no more than 25% in the first hour, targeting a MAP reduction of 20-25% [5]. Avoid precipitous drops to prevent cerebral ischemia.
*   **Definitive Therapy (for TMA):**
    *   **Empiric Plasma Exchange (PLEX):** Initiate daily plasma exchange (1-1.5 plasma volume) with fresh frozen plasma (FFP) replacement. This is the standard of care for TTP and is often started empirically while awaiting ADAMTS13 activity results.
    *   **Corticosteroids:** Methylprednisolone 1 g IV daily for 3 days, then taper.
    *   **If aHUS is suspected (e.g., no response to PLEX, severe hypertension, renal failure):** Consider eculizumab (900 mg IV weekly for 4 weeks, then 1200 mg every 2 weeks). This requires meningococcal vaccination or antibiotic prophylaxis.
*   **Supportive Care:** Avoid platelet transfusions unless life-threatening bleeding (risk of thrombosis). Manage fluid and electrolyte balance.

**Risk-benefit summary:**

*   **Major Benefits:**
    *   **Plasma Exchange:** Reduces mortality in TTP from >90% to <20% by removing inhibitory autoantibodies against ADAMTS13 and replenishing the deficient enzyme.
    *   **Antihypertensives:** Prevents irreversible end-organ damage (stroke, myocardial infarction, renal cortical necrosis).
    *   **Eculizumab:** For aHUS, it blocks terminal complement activation, halting microvascular thrombosis and preserving renal function.

*   **Major Risks:**
    *   **Plasma Exchange:** Catheter-related infections, bleeding, hypocalcemia (from citrate), anaphylactoid reactions to FFP.
    *   **Antihypertensives:** Overcorrection leading to cerebral hypoperfusion and stroke.
    *   **Eculizumab:** Increased risk of meningococcal and other encapsulated bacterial infections.
    *   **General:** Progression of TMA despite therapy, leading to dialysis dependence or death.

**Follow-up protocol:**

*   **Monitoring:**
    *   **Vitals:** Continuous BP monitoring, hourly urine output.
    *   **Labs:** Daily CBC (platelet count), LDH, haptoglobin, creatinine, and ADAMTS13 activity level (send stat).
    *   **Neurologic:** Frequent neurologic checks for headache, vision changes, or altered mental status.
*   **Contingency Plans:**
    *   If platelet count does not improve after 3-5 days of PLEX, consider refractory TTP (add rituximab) or switch to aHUS workup (complement factor H, I, MCP gene testing).
    *   If creatinine continues to rise, prepare for renal replacement therapy (hemodialysis).
    *   If neurologic symptoms worsen, consider brain imaging to rule out intracranial hemorrhage or posterior reversible encephalopathy syndrome (PRES).

**Confidence assessment:**

**0.85** (High confidence that this is a thrombotic microangiopathy syndrome requiring urgent PLEX and antihypertensive therapy. Lower confidence in distinguishing TTP from aHUS without ADAMTS13 results, which is why the recommendation includes empiric PLEX.)

**Key evidence:**

*   **[5]** – Supports the management of severe hypertension with end-organ damage (labetalol) and the recognition of thrombocytopenia + proteinuria as a critical syndrome.
*   **[1], [2], [3], [4], [6]** – These were used to rule out alternative diagnoses (preeclampsia, chronic hypertension, lupus nephritis, nephrotic syndrome, Alport syndrome) that do not fit the full clinical picture of MAHA + thrombocytopenia + AKI + severe hypertension.

</details>


---

### Prompt 7 — Gastrointestinal Bleeding

**Clinical vignette:** A 68-year-old on warfarin (INR 4.2) for AFib presents with hematemesis and melena. Vitals: HR 118, BP 92/58, RR 22. Hgb 7.2 (baseline 13). Patient is pale and diaphoretic. Already received 2 units PRBCs. Upper endoscopy shows spurting vessel in gastric antrum. What is the next immediate step?

**Expected concepts:** Variceal/nonvariceal bleeding, Hemostasis needed, Transfusion

**Concept coverage:** baseline 0.67 vs GRAPES 1.00 · GRAPES mean |SHAP| = 1.244

<details><summary>Baseline RAG answer</summary>


(1) Most likely diagnosis: Upper GI bleeding due to a spurting gastric vessel in a patient with warfarin toxicity (INR 4.2) and hemorrhagic shock.  
(2) Immediate management: Administer IV fluids for resuscitation [3] and reverse anticoagulation (e.g., vitamin K, prothrombin complex concentrate) while awaiting endoscopic hemostasis; note that lumbar puncture is contraindicated in bleeding diathesis [2].  
(3) Rationale: The patient has active bleeding with hypotension and tachycardia, requiring fluid resuscitation [3], and warfarin-induced coagulopathy precludes invasive procedures like lumbar puncture [2].  
Confidence: 0.9

</details>

<details><summary>GRAPES-SHAP answer</summary>


**Chain-of-thought reasoning:**

1.  **Patient Status:** This is a life-threatening upper GI bleed. The patient is a 68-year-old on warfarin (INR 4.2) with active hematemesis, melena, hypotension (BP 92/58), tachycardia (HR 118), and severe anemia (Hgb 7.2). He has already received 2 units of PRBCs but remains hemodynamically unstable.

2.  **Endoscopic Finding:** Upper endoscopy reveals a **spurting vessel** in the gastric antrum. This is a high-risk stigmata of recent hemorrhage (Forrest classification Ia) with a very high risk of rebleeding (up to 90% without intervention).

3.  **Immediate Hemostasis:** The standard of care for a spurting vessel is **endoscopic hemostasis**. Options include injection of epinephrine (1:10,000), thermal coagulation (e.g., heater probe, bipolar probe), or mechanical therapy (e.g., hemoclips). Hemoclips are often preferred for a visible vessel as they provide mechanical compression. Epinephrine injection alone is less effective for definitive hemostasis and is often combined with another modality.

4.  **Reversal of Anticoagulation:** The patient is on warfarin with a supratherapeutic INR of 4.2. Active bleeding with hemodynamic instability requires **urgent reversal** of anticoagulation. The most rapid and effective reversal agent is **prothrombin complex concentrate (PCC)** (e.g., 4-factor PCC, Kcentra/Beriplex) at a weight-based dose (e.g., 25-50 units/kg). Vitamin K (5-10 mg IV) should also be given to sustain reversal, but it takes 6-24 hours to work. Fresh frozen plasma (FFP) is an alternative but requires larger volumes and carries a risk of volume overload and transfusion reactions, and is less effective than PCC.

5.  **Hemodynamic Support:** The patient is hypotensive and tachycardic. While he received 2 units PRBCs, he remains unstable. **Resuscitation with IV fluids** (e.g., normal saline or lactated Ringer's) and additional PRBCs should continue to target a hemoglobin of 7-8 g/dL and hemodynamic stability. However, the immediate next step is to stop the bleeding.

6.  **Evidence Synthesis:**
    *   Evidence [1] highlights the need for blood transfusion in acute blood loss with severe anemia and hypotension. This supports the ongoing transfusion but does not address the source of bleeding.
    *   Evidence [2] confirms that warfarin use implies a bleeding diathesis, which is critical to reverse.
    *   Evidence [3] emphasizes immediate IV fluids for hemodynamic instability, which is a supportive measure.
    *   Evidence [4] describes a scenario of hypotension and positive stool Hematest, but does not provide the specific next step for an actively bleeding vessel.
    *   Evidence [5] and [6] are irrelevant to this GI bleed scenario.

**Treatment recommendation:**

1.  **Immediate Endoscopic Hemostasis:** Perform endoscopic therapy on the spurting vessel. The preferred method is **application of hemoclips** to the visible vessel. If hemoclips are not available or technically difficult, **thermal coagulation** (e.g., bipolar probe) combined with **injection of epinephrine (1:10,000)** around the base of the vessel is an alternative.
2.  **Urgent Reversal of Anticoagulation:** Administer **4-factor prothrombin complex concentrate (PCC)** intravenously. A typical dose is **25-50 units/kg** (e.g., for a 70 kg patient, 1750-3500 units). Follow this with **Vitamin K 5-10 mg IV** over 30 minutes.
3.  **Hemodynamic Resuscitation:** Continue **IV fluids** (e.g., normal saline boluses) and **packed red blood cells** to maintain a target hemoglobin of 7-8 g/dL and systolic BP > 90 mmHg.

**Risk-benefit summary:**

*   **Major Benefits:**
    *   **Endoscopic therapy:** Immediate cessation of active bleeding, reducing mortality from exsanguination and preventing rebleeding.
    *   **PCC:** Rapid (within 30 minutes) normalization of INR, allowing hemostasis to be achieved and reducing the risk of further bleeding.
    *   **Vitamin K:** Sustained reversal of warfarin effect, preventing rebound bleeding after PCC wears off.
    *   **Transfusion:** Restores oxygen-carrying capacity and hemodynamic stability.

*   **Major Risks:**
    *   **Endoscopic therapy:** Perforation (rare, <1%), aspiration, rebleeding (if clip placement is inadequate).
    *   **PCC:** Thrombotic events (e.g., DVT, PE, stroke) – risk is approximately 1-2%, especially in a patient with AFib. This risk is outweighed by the immediate life-threatening bleed.
    *   **Vitamin K:** Anaphylactoid reaction (rare, especially with IV administration). Can cause warfarin resistance for days.
    *   **Transfusion:** Transfusion reactions, volume overload, infection (rare).

**Follow-up protocol:**

1.  **Immediate (within 1 hour):**
    *   Repeat INR after PCC administration (target INR < 1.5).
    *   Monitor for signs of rebleeding (hematemesis, melena, drop in Hgb, hypotension, tachycardia).
    *   Monitor for thrombotic events (chest pain, shortness of breath, leg swelling, neurological changes).

2.  **Short-term (next 24-48 hours):**
    *   Admit to ICU or step-down unit for close monitoring.
    *   Start a proton pump inhibitor (PPI) infusion (e.g., pantoprazole 80 mg IV bolus followed by 8 mg/hour) to promote ulcer healing and reduce rebleeding risk.
    *   Repeat Hgb every 6-8 hours until stable.
    *   Consider repeat endoscopy if rebleeding is suspected.
    *   Resume warfarin only after hemostasis is confirmed and the patient is stable (typically 7-14 days post-bleed), with a lower INR target (e.g., 2.0-2.5) and consideration of bridging with heparin.

**Confidence assessment:**

**0.95** (High confidence). The combination of endoscopic hemostasis for a spurting vessel and urgent reversal of warfarin with PCC is the standard of care supported by strong evidence from GI bleeding guidelines and hematology literature. The only uncertainty is the exact dose of PCC, which is weight-based and should be calculated by the treating physician.

**Key evidence:**

*   [1] Supports the need for blood transfusion in acute blood loss with severe anemia and hypotension.
*   [2] Confirms the bleeding risk associated with warfarin use.
*   [3] Supports immediate IV fluid resuscitation for hemodynamic instability.
*   [4] Provides context for a patient with hypotension and GI bleeding but does not specify the next step for an actively bleeding vessel.

</details>


---

### Prompt 8 — Toxicology & Overdose

**Clinical vignette:** A 28-year-old found unresponsive with empty bottles of benzodiazepines and alcohol nearby. GCS 6, bradycardic (HR 42), hypotensive (BP 78/45), respiratory depression (RR 8). Pinpoint pupils present. Toxicology screen pending. What is the immediate management priority?

**Expected concepts:** Overdose, CNS depression, Airway protection

**Concept coverage:** baseline 1.00 vs GRAPES 1.00 · GRAPES mean |SHAP| = 1.328

<details><summary>Baseline RAG answer</summary>


(1) Most likely diagnosis: Opioid overdose (likely co-ingestion with benzodiazepines and alcohol), given the triad of respiratory depression, pinpoint pupils, and depressed consciousness.  
(2) Immediate management: Administer naloxone (opioid antagonist) and provide supportive care including airway management, IV fluids for hypotension [6], and monitoring.  
(3) Rationale: Pinpoint pupils and respiratory depression are classic signs of opioid toxicity [4], and the clinical picture of unresponsiveness with bradycardia and hypotension requires reversal with naloxone.  
Confidence: 0.85

</details>

<details><summary>GRAPES-SHAP answer</summary>


**Chain-of-thought reasoning**

1.  **Clinical Presentation Analysis:** The patient presents with a classic triad of opioid overdose: respiratory depression (RR 8), depressed level of consciousness (GCS 6), and **pinpoint pupils** [3]. The presence of pinpoint pupils is a critical physical exam finding that strongly suggests opioid toxicity, as it is a hallmark sign of opioid receptor agonism in the Edinger-Westphal nucleus. While pontine hemorrhage can also cause pinpoint pupils [3], the history of empty bottles of benzodiazepines and alcohol, combined with the absence of focal neurological signs (like decerebrate rigidity), makes opioid overdose the most likely primary cause.

2.  **Differential Diagnosis & Prioritization:** The patient has a mixed overdose (benzodiazepines, alcohol, and likely opioids). However, the immediate life-threatening threat is **respiratory depression**. The evidence retrieved does not directly address the management of opioid overdose. However, the evidence for benzodiazepine use in alcohol withdrawal [1][2] is not applicable here, as this patient is *not* in withdrawal but rather in an acute overdose state. The evidence for IV fluids in hypotensive pancreatitis [6] is also not directly relevant, though fluid resuscitation is a general supportive measure. The evidence for opioid-induced respiratory depression in neonates [4] confirms the known mechanism of opioid-induced respiratory depression.

3.  **Immediate Management Priority:** The single most critical intervention is to reverse the opioid-induced respiratory depression. This is done by administering **naloxone (Narcan)**, a specific opioid antagonist. While the toxicology screen is pending, the clinical picture (pinpoint pupils + respiratory depression) is sufficiently diagnostic to warrant immediate treatment. The goal is to restore adequate spontaneous ventilation (RR > 12) and improve consciousness. The patient is also hypotensive and bradycardic, which can be secondary to opioid and benzodiazepine effects, and will likely improve with naloxone and airway management.

4.  **Supportive Care:** Simultaneously, the patient requires basic life support: airway management (jaw thrust, consider intubation if naloxone is ineffective or the patient remains obtunded), high-flow oxygen, and IV access. IV fluids (e.g., normal saline) should be started for hypotension [6], but this is secondary to reversing the respiratory depression.

**Treatment recommendation**

- **Immediate:** Administer **Naloxone (Narcan)** 0.4 mg to 2 mg IV/IM/IN. If no response in 2-3 minutes, repeat the dose. For severe respiratory depression, a higher initial dose (e.g., 2 mg) may be used. The goal is to achieve a respiratory rate > 12 breaths per minute and an improvement in GCS.
- **Supportive:** Establish IV access. Administer a 500 mL to 1 L bolus of Normal Saline or Lactated Ringer's for hypotension [6]. Prepare for endotracheal intubation if the patient does not respond to naloxone or remains unable to protect their airway.
- **Note:** Do not administer benzodiazepines (e.g., chlordiazepoxide [1]) at this stage, as they will worsen respiratory depression. They are indicated for alcohol withdrawal, not acute overdose.

**Risk-benefit summary**

- **Major Benefits:** Rapid reversal of respiratory depression, prevention of hypoxic brain injury, and improvement in blood pressure and heart rate. Naloxone has no significant intrinsic activity and is extremely safe.
- **Major Risks:** Acute opioid withdrawal (agitation, vomiting, tachycardia, hypertension) if the patient is physically dependent. This is manageable but can be distressing. The half-life of naloxone (30-90 minutes) is shorter than many opioids (e.g., methadone, fentanyl), so respiratory depression may recur, requiring repeat doses or a continuous infusion. The patient also has benzodiazepines and alcohol on board, which may cause prolonged sedation even after opioid reversal.

**Follow-up protocol**

- **Monitoring:** Continuous pulse oximetry, respiratory rate, heart rate, blood pressure, and level of consciousness (GCS) every 5-15 minutes until stable, then every 1-2 hours.
- **Contingency Plans:**
    - If respiratory depression recurs after naloxone wears off, start a naloxone infusion (e.g., 0.25-0.5 mg/hour) titrated to effect.
    - If the patient remains hypotensive despite fluids and naloxone, consider other causes (e.g., sepsis, cardiomyopathy) and vasopressor support.
    - If the patient develops agitation or seizures, this may be from alcohol withdrawal or opioid withdrawal. Treat withdrawal with symptom-triggered benzodiazepines (e.g., lorazepam) only after ensuring the patient is not hypoxic.
    - Obtain a full toxicology screen, serum ethanol level, and acetaminophen level (common co-ingestant).
    - Admit to a medical ICU for observation for at least 24 hours due to risk of re-narcotization.

**Confidence assessment**

**0.95** (High confidence). The clinical presentation of respiratory depression, coma, and pinpoint pupils in the setting of empty bottles is pathognomonic for opioid overdose. Naloxone is the standard of care and is supported by overwhelming clinical evidence, even though the specific citations provided do not directly address this scenario. The main uncertainty is the exact opioid involved and the degree of benzodiazepine/alcohol co-ingestion, which may prolong the need for monitoring.

**Key evidence**

- **[3]** Pinpoint pupils are a key sign of opioid overdose (and pontine hemorrhage, but the history favors overdose).
- **[4]** Opioids cause respiratory depression, confirming the mechanism of the patient's primary threat.
- **[6]** IV fluids are a general supportive measure for hypotension, applicable here as a secondary intervention.

</details>


---

### Prompt 9 — Autoimmune/Inflammatory

**Clinical vignette:** A 35-year-old female with SLE presents with pleuritic chest pain, dyspnea, and rash. Labs show low complement (C3 12, C4 8), elevated ANA 1:1280, anti-dsDNA positive, proteinuria 2.5g/24h, and mild thrombocytopenia (98K). Chest imaging shows pleural effusion. What lupus manifestations are present?

**Expected concepts:** SLE flare, Lupus nephritis, Serositis

**Concept coverage:** baseline 1.00 vs GRAPES 0.67 · GRAPES mean |SHAP| = 1.552

<details><summary>Baseline RAG answer</summary>


(1) Most likely diagnosis: Systemic lupus erythematosus (SLE) with active lupus nephritis (proteinuria 2.5g/24h), serositis (pleuritic chest pain, pleural effusion), cutaneous lupus (rash), and hematologic involvement (mild thrombocytopenia). Low complement (C3, C4) and positive anti-dsDNA indicate active disease.

(2) Immediate management: High-dose corticosteroids (e.g., prednisone 1 mg/kg/day) and consider immunosuppressive therapy (e.g., mycophenolate mofetil or cyclophosphamide) for lupus nephritis. Monitor renal function, complement levels, and anti-dsDNA. Provide supportive care for pleuritic pain.

(3) Rationale: The combination of low complement, positive anti-dsDNA, proteinuria, serositis, and rash is classic for active SLE with renal and serosal involvement [4]; low C4 is associated with active disease and not lymphoma in this context [3].

Confidence: 0.95

</details>

<details><summary>GRAPES-SHAP answer</summary>


**Chain-of-thought reasoning:**

1.  **Identifying Lupus Manifestations:** The patient presents with classic signs of Systemic Lupus Erythematosus (SLE). The malar rash, photosensitivity, and oral ulcers are hallmark cutaneous and mucosal findings, as described in [4]. The presence of pleuritic chest pain, dyspnea, and pleural effusion on imaging indicates **pleuritis**, a common serosal manifestation of SLE. The lab findings are highly specific: low complement levels (C3, C4) and positive anti-dsDNA are strongly associated with active lupus, particularly lupus nephritis [3]. The proteinuria of 2.5g/24h confirms **lupus nephritis** (likely Class III or IV, given the level of proteinuria and low complements). The mild thrombocytopenia (98K) is a hematologic manifestation of SLE.

2.  **Excluding Other Diagnoses:** The evidence [1] discusses "Lupus vulgaris," which is a cutaneous form of tuberculosis, not SLE. This is irrelevant to the current case. Evidence [5] describes pulmonary embolism, which can present with pleuritic chest pain and dyspnea, but the patient's rash, serology, and proteinuria make SLE-related pleuritis far more likely. Evidence [6] lists CNS lupus manifestations, but the patient has no CNS involvement mentioned.

3.  **Synthesizing the Manifestations:** Based on the clinical and lab data, the patient has active SLE with at least four major manifestations: **cutaneous** (malar rash, photosensitivity, oral ulcers), **serosal** (pleuritis with effusion), **renal** (lupus nephritis with proteinuria), and **hematologic** (thrombocytopenia). The low complements and positive anti-dsDNA indicate high disease activity.

**Treatment recommendation:**

This patient has moderate-to-severe active SLE with major organ involvement (lupus nephritis). The recommended first-line therapy is high-dose corticosteroids combined with an immunosuppressant.

- **Induction Therapy:**
    - **Drug:** Mycophenolate mofetil (MMF)
    - **Dose:** 2-3 grams per day orally, divided into two doses.
    - **Schedule:** Start at 500mg twice daily, titrate up over 1-2 weeks to target dose.
    - **Concurrent:** Methylprednisolone 1 gram IV daily for 3 days, followed by oral prednisone 0.5-1 mg/kg/day (e.g., 40-60 mg daily) with a taper over 3-6 months.
- **Alternative:** Cyclophosphamide (e.g., 500 mg IV every 2 weeks for 6 doses) could be considered if MMF is contraindicated or fails, but MMF is preferred for its better safety profile in women of childbearing age.
- **Adjunctive:** Hydroxychloroquine 200-400 mg daily (if not already on it) for long-term disease control and to reduce flares.

**Risk-benefit summary:**

- **Major Benefits:**
    - High-dose steroids and MMF are proven to induce remission in lupus nephritis, preserving renal function and preventing end-stage renal disease.
    - Rapid control of pleuritis and thrombocytopenia with steroids.
    - Reduction in overall disease activity, improving quality of life and survival.

- **Major Risks:**
    - **Immunosuppression:** Increased risk of infections (especially opportunistic infections like *Pneumocystis jirovecii* pneumonia, herpes zoster). Prophylaxis for PJP (e.g., trimethoprim-sulfamethoxazole) is recommended.
    - **Steroid toxicity:** Hyperglycemia, hypertension, osteoporosis, avascular necrosis, weight gain, mood changes.
    - **MMF toxicity:** Gastrointestinal upset, bone marrow suppression (monitor CBC), teratogenicity (strict contraception required in women of childbearing age).
    - **Thrombocytopenia:** Risk of bleeding, though mild in this case (98K). Monitor platelet count closely.

**Follow-up protocol:**

- **Immediate (first 2 weeks):**
    - Monitor daily: Vital signs, urine output, chest pain/dyspnea.
    - Labs every 2-3 days: CBC with differential, serum creatinine, electrolytes, urinalysis with protein/creatinine ratio.
    - Chest X-ray to monitor pleural effusion resolution.
- **Short-term (1-3 months):**
    - Monthly: CBC, CMP, urinalysis, 24-hour urine protein, complement levels (C3, C4), anti-dsDNA.
    - Monitor for steroid side effects: Blood glucose, blood pressure, bone density (DEXA scan baseline).
- **Long-term (3-12 months):**
    - Taper prednisone as tolerated.
    - Continue MMF for at least 2-3 years after remission.
    - Annual: Renal function, lipid panel, ophthalmology exam (for hydroxychloroquine toxicity).
- **Contingency Plans:**
    - If no improvement in proteinuria or renal function by 3 months, consider switching to cyclophosphamide or adding a calcineurin inhibitor (e.g., tacrolimus).
    - If platelet count drops below 50K, consider IVIG or rituximab.
    - If infection suspected, hold immunosuppression and initiate broad-spectrum antibiotics.

**Confidence assessment:**

**0.85** (High confidence). The diagnosis of active SLE with nephritis, pleuritis, and hematologic involvement is strongly supported by the clinical and serologic data [3][4]. The treatment regimen (steroids + MMF) is standard of care for lupus nephritis based on robust evidence. The main uncertainty is the exact renal biopsy class (not performed here), but the level of proteinuria and low complements strongly suggest proliferative disease requiring aggressive therapy.

**Key evidence:**

- **[3]** Low C4 complement levels are associated with active SLE and lymphoma in Sjogren's, but in this context, low complements confirm active lupus.
- **[4]** Classic SLE manifestations (malar rash, photosensitivity, oral ulcers) are described, matching this patient's presentation.
- **[6]** CNS lupus is excluded, focusing the differential on other organ systems.

</details>


---

### Prompt 10 — Oncologic Emergency

**Clinical vignette:** A 52-year-old with newly diagnosed small cell lung cancer presents with weakness, confusion, and elevated sodium (Na 152). SIADH suspected. Serum osmolality 310, urine osmolality 750, urine sodium 180. Patient on minimal fluid. What is the underlying mechanism and treatment goal?

**Expected concepts:** SIADH, Hypernatremia, Fluid restriction

**Concept coverage:** baseline 0.67 vs GRAPES 1.00 · GRAPES mean |SHAP| = 1.420

<details><summary>Baseline RAG answer</summary>


(1) **Most likely diagnosis:** Syndrome of Inappropriate Antidiuretic Hormone (SIADH) secondary to small cell lung cancer.  
(2) **Immediate management:** Fluid restriction and correction of hyponatremia; in chronic kidney disease, maintain serum sodium at 120 mEq/L [3].  
(3) **Rationale:** The patient’s elevated urine sodium (>20 mEq/L) and urine osmolality (> plasma osmolality) despite hyponatremia and hyperosmolality are classic for SIADH [5][6], and the underlying mechanism is ectopic ADH secretion from the tumor.  

Confidence: 0.9

</details>

<details><summary>GRAPES-SHAP answer</summary>


**1. Chain-of-Thought Reasoning**

*   **Step 1: Analyze the Patient’s Presentation and Labs.** The patient has small cell lung cancer (SCLC), a classic paraneoplastic cause of SIADH. He presents with weakness and confusion, which are neurological symptoms of severe hyponatremia. However, his serum sodium is **152 mEq/L (hypernatremia)**, not hyponatremia. This is a critical discrepancy. The query states "SIADH suspected," but the labs show hypernatremia (Na 152), high serum osmolality (310 mOsm/kg), high urine osmolality (750 mOsm/kg), and high urine sodium (180 mEq/L). This pattern is **not consistent with SIADH**.
*   **Step 2: Reconcile the Labs with SIADH Criteria.** The cardinal features of SIADH, as cited in evidence [5] and [6], include **hyponatremia** (low serum sodium) and **decreased plasma osmolality** (<280 mOsm/kg). Our patient has the opposite: hypernatremia and high serum osmolality. Therefore, SIADH is ruled out by the lab values alone.
*   **Step 3: Identify the Correct Underlying Mechanism.** The combination of hypernatremia, high serum osmolality, and a high urine osmolality (750 mOsm/kg) indicates that the kidneys are concentrating urine appropriately. However, the urine sodium is very high (180 mEq/L). This pattern is consistent with **hypernatremia due to water loss** (e.g., from diabetes insipidus, insensible losses, or inadequate water intake) **combined with a high sodium intake or renal sodium retention**. Given the patient is on "minimal fluid," the most likely mechanism is **hypernatremic dehydration** (water loss exceeding sodium loss) with the kidneys excreting excess sodium to maintain volume. The high urine osmolality suggests the kidneys are still responsive to ADH, ruling out central or nephrogenic diabetes insipidus. The underlying mechanism is **inadequate free water intake relative to solute load**, leading to a hyperosmolar state.
*   **Step 4: Determine the Treatment Goal.** The treatment goal is **correction of hypernatremia** by replacing the free water deficit. The target is to lower serum sodium slowly (no more than 10-12 mEq/L per 24 hours) to avoid cerebral edema. The goal is to achieve **normonatremia (Na 135-145 mEq/L)**. The evidence [3] mentions maintaining serum sodium at 120 mEq/L in hyponatremia with renal failure, which is irrelevant here. The correct goal is to normalize sodium safely.

**2. Treatment Recommendation**

*   **Drug:** 5% Dextrose in Water (D5W) or 0.45% Normal Saline (half-normal saline).
*   **Dose:** Calculate the free water deficit using the formula: **Water deficit (L) = 0.6 × weight (kg) × [(Serum Na / 140) - 1]**. For a 70 kg man: 0.6 × 70 × [(152/140) - 1] = 42 × (1.086 - 1) = 42 × 0.086 = **3.6 L**.
*   **Schedule:** Replace the deficit over 48 hours. Administer **D5W at a rate of 75-100 mL/hour** initially, adjusting based on frequent serum sodium checks. The goal is to lower serum sodium by **no more than 8-10 mEq/L in the first 24 hours**. Do not use hypertonic saline (3% NaCl) as this would worsen hypernatremia.
*   **Route:** Intravenous (IV).

**3. Risk-Benefit Summary**

*   **Major Benefits:**
    *   Correction of hypernatremia will resolve neurological symptoms (weakness, confusion) [1].
    *   Restoration of normal serum osmolality and intracellular volume.
    *   Prevention of complications from severe hypernatremia (e.g., cerebral hemorrhage, osmotic demyelination if corrected too fast).
*   **Major Risks:**
    *   **Overly rapid correction** leading to cerebral edema (seizures, coma, death). This is the primary risk.
    *   Volume overload if the patient has underlying heart failure or renal impairment.
    *   Hyperglycemia from D5W infusion (monitor blood glucose).

**4. Follow-up Protocol**

*   **Monitoring:**
    *   **Serum sodium, potassium, and glucose:** Check every **4-6 hours** during the first 24 hours of correction.
    *   **Urine output and urine osmolality:** Monitor to assess renal response.
    *   **Neurological status:** Frequent assessments for improvement or worsening of confusion/weakness.
    *   **Volume status:** Daily weights, input/output charting, and clinical exam for edema.
*   **Contingency Plans:**
    *   If serum sodium drops **>10 mEq/L in 24 hours**, **stop the hypotonic fluid** and consider administering **D5W with 2-3 mEq/L of desmopressin (DDAVP)** to slow the rate of correction.
    *   If the patient develops seizures or altered mental status, immediately recheck sodium and consider **hypertonic saline (3% NaCl)** only if sodium has dropped too fast and cerebral edema is suspected.
    *   If hyperglycemia occurs (glucose >200 mg/dL), switch from D5W to **0.45% Normal Saline** and manage glucose with insulin if needed.

**5. Confidence Assessment**

**Confidence: 0.85**

*   **Rationale:** The lab values (hypernatremia, high osmolality) are unequivocal and rule out SIADH with high certainty. The treatment for hypernatremic dehydration is well-established. The confidence is not 1.0 because the exact cause of the hypernatremia (e.g., unreported diuretic use, osmotic diuresis from hyperglycemia) is not fully detailed, and the patient's weight is assumed for the deficit calculation. The evidence [1]-[6] primarily addresses hyponatremia and SIADH, so the recommendation is based on general principles of hypernatremia management, which are not directly cited in the provided evidence.

**6. Key Evidence**

*   **[5]** and **[6]** were critical for **ruling out SIADH** by confirming that SIADH requires hyponatremia and low plasma osmolality, which are absent here.
*   **[1]** and **[3]** were used to understand the clinical context (SCLC, neurological symptoms) and the general principle of safe sodium correction, though they focus on hyponatremia.
*   **[2]** and **[4]** were not directly applicable as they address oliguria and pre-renal failure, which are not present in this case.

</details>


---

## 4. Conclusion

Across 10 complex clinical scenarios, GRAPES-SHAP improves clinical-concept coverage by **+26.7 percentage points** over a strong hybrid-RAG baseline, while additionally providing calibrated uncertainty, world-model treatment planning, and per-evidence SHAP explanations that the baseline cannot offer. These capabilities are essential for trustworthy clinical decision support.
